Skip to main content
. 2023 Jun 21;2023(6):CD014788. doi: 10.1002/14651858.CD014788.pub2

Vella 1995.

Methods Trial design: randomised trial
Participants Participants: 30
Meang age: not stated
Inclusion criteria: not stated 
Exclusion criteria: not stated
Setting: not stated
Timing: not stated
Interventions Group 1: goserelin 
versus
Group 2: goserelin + premarin (conjugated oestrogens) 1.25 mg
Outcomes
  • Bone mineral density

Notes Intention‐to‐treat analysis: not stated
Sample size calculation: not stated 
Funding: not stated
 
This abstract did not contain enough information to make a proper decision about in‐/exclusion. 

DPMA: depot medroxyprogesterone acetate
GnRHa: gonadotropin‐releasing hormone analogues
IM: intramuscular 
LA: leuprolide acetate